拉米夫定联合胸腺肽治疗HBeAg阴性的慢性乙型肝炎临床观察

目的:研究拉米夫定联合胸腺肽治疗HBeAg阴性的慢性乙型肝炎的临床疗效。方法:治疗组拉米夫定100mg及胸腺肽20 mg,每日1次口服或肌注;对照组保肝对症:肌苷、维生素C、中药治疗。结果:治疗组ALT复常率92.9%,HBV-DNA阴转率89.3%;对照组ALT复常率为34.6%,HBV-DNA阴转率15.4%。结论:联合胸腺肽α1,弥补拉米夫定缺失免疫调节作用的缺点,两者联合应用疗效满意。

Clinical Observation on Lamivudine combined Thymosin in Treating HBeAg-negative Chronic Hepatitis B

Objective:To study the treatment of HBeAg-negative chronic hepatitis B clinical efficacy by lamivudine combined with thymosin.Method: Treatment group: lamivudine 100mg,Thymosin 20mg,once a day,oral or intramuscularly.Baseline group: Liver protection,Inosine,VC,traditional chinese medicine.Result: Treatment group: ALT normalization rate is 92.9%;HBV DNA-negative rate is 89.3%.Baseline group: ALT normalization rate is 34.6%;HBV DNA-negative rate is 15.4%.Conclusion: The shortcoming of lamivudine is loss of immunoregulatory role,thymosin can make up for this shortcoming,this combination of two drugs is better.